Search
Browse
Statistics
Feeds

Personalized CRISPR knock-in cytokine gene therapy to remodel the tumor microenvironment and enhance CAR T cell therapy in solid tumors

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB
[thumbnail of Supplementary Information incl. Source Data] Other (Supplementary Information incl. Source Data)
35MB

Item Type:Article
Title:Personalized CRISPR knock-in cytokine gene therapy to remodel the tumor microenvironment and enhance CAR T cell therapy in solid tumors
Creators: Launspach, Michael ORCID logoORCID: https://orcid.org/0000-0001-5337-5605, Macos, Julia ORCID logoORCID: https://orcid.org/0009-0008-9196-3975, Afzal, Shoaib ORCID logoORCID: https://orcid.org/0009-0009-5490-6098, Hohmann, Janik ORCID logoORCID: https://orcid.org/0009-0001-5374-1350, Appis, Marc L. ORCID logoORCID: https://orcid.org/0000-0002-0155-1918, Pilgram, Maximilian ORCID logoORCID: https://orcid.org/0009-0002-3423-5249, Beez, Stefanie, Ohlendorf, Emily, van der Ven, Casper F.T. ORCID logoORCID: https://orcid.org/0000-0001-7947-6105, Lachiheb, Chahrazad, Töws, Karin, Andersch, Lena, Jens, Marvin ORCID logoORCID: https://orcid.org/0000-0002-6660-8743, Zirngibl, Felix ORCID logoORCID: https://orcid.org/0000-0003-1764-4841, Kath, Jonas ORCID logoORCID: https://orcid.org/0000-0001-7721-7978, Stecklum, Maria ORCID logoORCID: https://orcid.org/0009-0001-7951-5730, Rodriguez-Fos, Elias ORCID logoORCID: https://orcid.org/0000-0002-2555-0178, Anders, Kathleen ORCID logoORCID: https://orcid.org/0000-0002-0429-200X, Wagner, Dimitrios L. ORCID logoORCID: https://orcid.org/0000-0002-2189-3579, Henssen, Anton G. ORCID logoORCID: https://orcid.org/0000-0003-1534-778X, Kühn, Ralf ORCID logoORCID: https://orcid.org/0000-0003-1694-9803, Eggert, Angelika and Künkele, Annette ORCID logoORCID: https://orcid.org/0000-0002-8406-5412
Abstract:The immunosuppressive tumour microenvironment (TME) remains a central barrier to effective immunotherapy in solid tumours. We present a gene-therapeutic strategy that enables localized remodelling of the TME via tumour-intrinsic cytokine expression. Central to this approach is CancerPAM, a multi-omics bioinformatics pipeline that identifies and ranks patient-specific, tumour-exclusive CRISPR-Cas9 knock-in sites with high specificity and integration efficiency. Using neuroblastoma as a model, CancerPAM analysis of tumour sequencing data identifies optimal knock-in sites for pro-inflammatory cytokines (CXCL10, CXCL11, IFNG), and CancerPAM rankings correlate strongly with target-site specificity and knock-in efficiency, validating its predictive performance. CRISPR-mediated CXCL10 knock-in enhances CAR T cell infiltration and antitumour efficacy in vitro and in vivo, including humanized CD34⁺ HuNOG mice, where CXCL10-expressing tumours show stronger immune infiltration and prolonged tumour control within a reconstituted human immune microenvironment. Our findings establish a framework for safe and effective CRISPR-based cytokine delivery, integrating localized TME remodelling with cellular immunotherapies to enhance CAR T cells and other treatments in immune-refractory solid tumours.
Keywords:Adoptive Immunotherapy, CRISPR-Cas Systems, Chemokine CXCL10, Chemokine CXCL11, Chimeric Antigen Receptors, Clustered Regularly Interspaced Short Palindromic Repeats, Cytokines, Gene Knock-In Techniques, Genetic Therapy, Interferon-Gamma, Neoplasms, Neuroblastoma, Precision Medicine, T-Lymphocytes, Tumor Cell Line, Tumor Microenvironment, Animals, Mice
Source:Nature Communications
ISSN:2041-1723
Publisher:Nature Publishing Group
Volume:16
Number:1
Page Range:10987
Date:9 December 2025
Official Publication:https://doi.org/10.1038/s41467-025-67328-w
PubMed:View item in PubMed
Related to:

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library